Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody

Gene Therapy

Volumn 5, Issue 9, 1998, Pages 1171-1179

  Piche A ^a   Kasono, K ^a   Johanning, F ^a   Curiel, T J ^b   Curiel, D T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cancer gene therapy; EBV; Latent membrane protein 1; Lymphoproliferative diseases; Single chain antibody

Indexed keywords

ANTIBODY; CELL PROTEIN; CISPLATIN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; VIRUS PROTEIN;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL DEATH; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; EPSTEIN BARR VIRUS; EUKARYOTIC CELL; GENE EXPRESSION REGULATION; GENE THERAPY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031720363     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300706     Document Type: Article

References (52)

1. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM (eds). Fields Virology, 2nd edn. Raven Press: New York, 1990, pp 1889-1922.
2. Miller, G. Epstein-Barr virus. In: Fields BN, Knipe DM (eds), Fields Virology, 2nd edn. Raven Press: New York, 1990, pp 1921-1958.
3. MacMahon EM et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma Lancet 1991; 338: 969-973.
4. Hochberg FH et al. Central nervous system lymphoma related to Epstein-Barr virus New Engl J Med 1983; 309: 745-748.
5. Levine AM. AIDS-related malignancies: the merging epidemic. J Natl Cancer Inst 1993; 85: 1382-1397.
6. Murray PG et al. Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in post-transplantation lymphoproliferative disorders Blood 1996; 87: 706-711.
7. Cannon MJ, Pisa P, Fox RI, Cooper NR. Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest 1990; 85: 1333-1337.
8. Rowe M et al Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991; 173: 147-158.
9. Picchio GR et al. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of of immunoblastic B cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res 1992; 52: 2468-2477.
10. Rowe M et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J 1987; 6: 2743-2751.
11. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus (EBV) B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol 1990; 71: 1451-1459.
12. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150-9154.
13. Kaye KM, Izumi KM, Mosialos G, Kieff E. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminal is essential for B lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995; 69: 675-683.
14. Wang D et al. Epstein-Barr latent infection membrane protein alters the human B lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988; 62: 4173-4178.
15. Wang F et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear protein 2 and 3C are effectors of phenotypic change in B lymphocytes; EBNA2 and LMP1 cooperatively induce CD23. J Virol 1990; 64: 2309-2318.
16. Henderson SM et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107-1115.
17. Mosialos G et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
18. Wagner RW. Gene inhibition using antisense oligodeoxynucleotide. Nature 1994; 372: 333-335.
19. Iversen PL, Zhu S, Meyer A, Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 1992; 2: 211-222.
20. Reed JC. Promise and problems of Bcl-2 antisense therapy. J Natl Cancer Inst 1997; 89: 988-990.
21. Yamada O et al. A chimeric human immunodefiency virus type 1 (HIV-1) minimal rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J Virol 1996; 70: 1596-1601.
22. Sakamot N, Wu CH, Wu GY. Intracellular celavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-2728.
23. Michienzi A, Prislei S, Bozzoni I. Ul small nuclear RNA chimeric ribozymes with substrate specificity for the rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci USA 1996; 93: 7219-7224.
24. Yu M et al. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995; 92: 699-703.
25. Thompson JD, Macejak D, Couture L, Stinchcomb DT. Ribozymes in gene therapy. Nature Med 1995; 1: 227-228.
26. Biocca S et al. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. BioTechniques 1995; 13: 1110-1115.
27. Biocca S, Cartaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biology 1995; 5: 248-252.
28. Abner MM et al. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995; 14: 1542-1551.
29. Duan L, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-Rev single-chain variable fragments. Hum Gene Ther 1995; 6: 1561-1573.
30. Levy-Mintz PL et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 1996; 70: 8821-8832.
31. Richardson JH et al. Phenotypic knock-out of hte high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the a subunit of the receptor. Proc Natl Acad Sci USA 1995; 92: 3137-3147.
32. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994; 269: 23931-23936
33. Wright M et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Therapy 1997; 4: 317-322.
34. Deshane J et al. Intracellular single-chain antibody directed against erbB-2 down-regulates cell surface erbB-2 and exhibits a selective anti-proliferative effect in erbB-2 overexpressing cancer cell lines. Gene Therapy 1994; 1: 332-337.
35. Kosako H et al Isolation and characterization of neutralizing single-chain antibodies against Xenopus mitogen-activated protein kinase from phage display libraries. Biochem J 1996; 35: 13212-13221.
36. Piché A et al. Chemosensitization mediated by an intracellular single-chain antibody that abolishes the function of BAG-1, an anti-apoptotic protein. (Manuscript in preparation).
37. Mothes W et al. Molecular mechanism of membrane protein integration into the endoplasmic reticulum. Cell 1997; 89: 523-533.
38. Liebowitz D, Wang D, Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 1986; 58: 233-237.
39. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 831-840.
40. Wang D, Liebowitz D, Kieff E. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol 1988; 62: 2337-2346.
41. Cook DR et al. Gene therapy for B cell lymphoma in a SCID mouse model using an immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate. Cancer Biother 1994; 2: 131-141.
42. Deshane J et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995; 59: 8-14.
43. Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of bcl-2. J Virol 1993; 67: 5269-5278.
44. Okan IY et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995; 11: 1027-1031.
45. Piché A et al. Modulation of Bcl-2 protein expression by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced tumor cell killing. Cancer Res 1998; 58: 2134-2140.
46. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 1988; 6: 616-624.
47. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
48. Douglas JT et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotech 1996; 14: 1574-1578.
49. Douglas JT, Curiel DT. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromusc Disord 1997; 7: 284-298.
50. Zufferey R et al. Multipli-attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotech 1997; 15: 871-875.
51. Dilloo D et al. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 1997, 89: 119-127.
52. Pharmacia Biotech. Simultaneous screening of large numbers of recombinant antibody clones using a colony lift assay. Science Tools from Pharmacia Biotech 1996; 1: 10-11.